Telaglenastat (CB-839), a glutaminase inhibitor, was included to exploit the well-documented glutamine addiction of many RCC tumors, disrupting their energy production and biosynthetic capabilities [25]. The gene discussed is GLS; the disease is renal cell carcinoma.